Thomas Jefferson University Hospital, Philadelphia, PA
Brooke Worster , Rebecca Ashare , Salimah H. Meghani , Danielle Smith , Amy Allen Case , Preethi Selvan , Ayako Shimada , Greg D. Garber , Amy Leader
Background: While access to cannabis is prevalent among cancer patients1, unknowns persist about real-time use, perceived effectiveness in cancer pain management and impact on other medication use, including opioids. Moreover, racial disparities in cancer pain management persist2-3 with Black patients more likely to have undiagnosed pain.4 Studies on the intersection of cannabis, opioids, race and cancer pain are needed. As part of an NCI-funded initiative, we assessed the perceived effectiveness of cannabis vs. opioids for pain control by race. Methods: A survey was created by three Mid-Atlantic, cancer centers to examine self-reported cannabis use and knowledge, barriers and perceptions about cannabis among cancer patients. All sites assessed common core questions and included additional questions assessing cannabis and opioid use. Patients were eligible to participate if they were treated for cancer within the prior year. Surveys were distributed both by mail and electronically via REDCap. Results are compared separately by site. Results: In all, 2,734 patients are included in this analysis. Rates of cannabis use since diagnosis ranged from 32-41% of respondents, with similar rates of use between gender and race. Patients under age 65 more frequently reported cannabis use. Across sites, only 7-8% of patients reported currently using opioids. A sizable number patients who use cannabis reported using cannabis instead of opioids to treat pain. Of those using cannabis, most felt that cannabis was better in managing their pain than opioids, with Black patients reporting this much more frequently than White patients across two sites (Site A 62.2% vs 43.2%, Site B 77.78 vs 48.96%, Site C 50.0% vs. 65.5%). The most common reasons patients reported using cannabis instead of opioids included the perception that: “cannabis is safer” (80-82%), “cannabis is less addictive” (70-73%), and “cannabis has fewer side effects” (68-74%). Conclusions: Cannabis is frequently used by cancer patients, with many reporting use instead of opioids for pain management. Of those using cannabis for pain management, a significant majority felt that it is more effective than opioids. Black patients report cannabis as more effective than opioids for pain control more frequently than other races. Given the ongoing under-treatment of cancer pain in Black patients, more data is needed to understand whether cannabis is an effective tool to reduce disparities in cancer pain management.
Site A (n = 1574) | Site B (n = 816) | Site C (n = 344) | |
---|---|---|---|
Age (mean) | 20-90 (64.62) | 22-88 (60.52) | 18-88 (58.45) |
Female (%) | 899 (58.5) | 489 (59.93) | 185(53.78) |
Male (%) | 633 (41.2) | 325 (39.83) | 159 (46.72) |
White (%) | 1201 (76.2) | 716 (87.7) | 315 (91.5) |
Black (%) | 289 (18.3) | 81 (9.9) | 22 (6.3) |
Have you used cannabis at any time since your cancer diagnosis? (%) | Yes, < 65 yo = 43.0 Yes, > 65 yo = 24.7 | Yes, < 65 yo = 47.9 Yes, > 65 yo = 24.3 | Yes, < 65 yo = 53.4 Yes, > 65 yo = 26.8 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Talya Salz
2023 ASCO Annual Meeting
First Author: Joke Bradt
2022 ASCO Quality Care Symposium
First Author: Desiree Rachel Azizoddin
2022 ASCO Quality Care Symposium
First Author: Desiree Rachel Azizoddin